Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

20021,499 citationsJournal Article

Authors

Robert J. Motzer · Memorial Sloan Kettering Cancer Center

Jennifer Bacik · Memorial Sloan Kettering Cancer Center

Barbara A. Murphy · Memorial Sloan Kettering Cancer Center

Paul Russo · Memorial Sloan Kettering Cancer Center

Madhu Mazumdar · Memorial Sloan Kettering Cancer Center

Abstract

Progression-free and overall survival with interferon-alpha treatment can be compared with new therapies in phase II and III clinical investigations. The prognostic model is suitable for risk stratification of phase III trials using interferon-alpha as the comparative treatment arm.

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Ovarian cancer diagnosis and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 1, pp. 289-296

DOI: 10.1200/jco.2002.20.1.289

Field-Weighted Citation Impact: 18.04